To confirm the clinical utility of our classification scheme, future studies should carefully examine how these FOXA1 alteration classes govern outcomes in clinically relevant settings, including in primary prostate cancer, metastatic hormone-sensitive disease, and metastatic castration-resistant disease. The gene discussed is FOXA1; the disease is prostate cancer.